Lancet Haematol:预防VTE患者复发性VTE和大出血:阿哌沙班vs利伐沙班

2019-03-04 常路 环球医学

阿哌沙班和利伐沙班都是直接作用的口服抗凝药,由于其固定剂量和较好的药理学特征而越来越多地用于常规临床实践。两种药物复发性静脉血栓栓塞(VTE)和大出血事件风险的差异目前未知。2019年1月,发表在《Lancet Haematol》的一项回顾性基于人群的队列分析调查了,阿哌沙班vs利伐沙班预防静脉血栓栓塞患者复发性静脉血栓栓塞(有效性)和不良出血事件(安全性)。

阿哌沙班和利伐沙班都是直接作用的口服抗凝药,由于其固定剂量和较好的药理学特征而越来越多地用于常规临床实践。两种药物复发性静脉血栓栓塞(VTE)和大出血事件风险的差异目前未知。2019年1月,发表在《Lancet Haematol》的一项回顾性基于人群的队列分析调查了,阿哌沙班vs利伐沙班预防静脉血栓栓塞患者复发性静脉血栓栓塞(有效性)和不良出血事件(安全性)。

目的:研究人员旨在比较阿哌沙班和利伐沙班预防静脉血栓栓塞患者复发性静脉血栓栓塞和大出血事件的有效性和安全性。

方法:研究人员进行了一项回顾性队列分析,数据来自于美国Truven Health MarketScan商业和医疗保险补充索赔数据库。研究对象为2014年1月1日~2016年12月31日新使用阿哌沙班或利伐沙班的新诊断为静脉血栓栓塞(深静脉血栓或肺栓塞)的成年患者。患者排除标准为,确诊后30天内未初始研究药物,未连续12个月入组到医疗和药房福利中,基线期使用其他抗凝药。首要有效性结局指标为复发性静脉血栓栓塞的发生率,首要安全性结局指标为大出血事件发生率。倾向得分匹配后的Cox成比例风险模型用于计算风险比(HR)和95% CI。

结果:倾向得分匹配后,15254名患者纳入到队列中(阿哌沙班使用者3091人,利伐沙班使用者12163人)。阿哌沙班组和利伐沙班组复发性静脉血栓栓塞粗发生率分别为3/100人年和7/100人年,大出血发生率分别为3/100人年和6/100人年。多变量Cox回归模型中,与利伐沙班相比,阿哌沙班与复发性静脉血栓栓塞(HR,0.37;95% CI,0.24~0.55;P<0.0001)和大出血事件(0.54;0.37~0.82;P=0.0031)风险降低相关。

结论:基于上述研究结果,阿哌沙班貌似比利伐沙班在预防复发性静脉血栓栓塞和大出血事件上更有效。这些数据可能会给临床医生一些保证,即阿哌沙班是治疗静脉血栓栓塞患者的有效和安全的治疗选择。

原始出处:


版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1909760, encodeId=7f701909e603a, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Aug 07 08:18:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008412, encodeId=3d002008412bb, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Wed Mar 20 15:18:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829968, encodeId=4d8a182996884, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jul 14 09:18:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316164, encodeId=7b4d131616408, content=<a href='/topic/show?id=7a1c4360e6e' target=_blank style='color:#2F92EE;'>#大出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43607, encryptionId=7a1c4360e6e, topicName=大出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Mar 06 05:18:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317491, encodeId=129b131e491d0, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Mar 06 05:18:00 CST 2019, time=2019-03-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1909760, encodeId=7f701909e603a, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Aug 07 08:18:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008412, encodeId=3d002008412bb, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Wed Mar 20 15:18:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829968, encodeId=4d8a182996884, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jul 14 09:18:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316164, encodeId=7b4d131616408, content=<a href='/topic/show?id=7a1c4360e6e' target=_blank style='color:#2F92EE;'>#大出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43607, encryptionId=7a1c4360e6e, topicName=大出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Mar 06 05:18:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317491, encodeId=129b131e491d0, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Mar 06 05:18:00 CST 2019, time=2019-03-06, status=1, ipAttribution=)]
    2019-03-20 changfy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1909760, encodeId=7f701909e603a, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Aug 07 08:18:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008412, encodeId=3d002008412bb, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Wed Mar 20 15:18:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829968, encodeId=4d8a182996884, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jul 14 09:18:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316164, encodeId=7b4d131616408, content=<a href='/topic/show?id=7a1c4360e6e' target=_blank style='color:#2F92EE;'>#大出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43607, encryptionId=7a1c4360e6e, topicName=大出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Mar 06 05:18:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317491, encodeId=129b131e491d0, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Mar 06 05:18:00 CST 2019, time=2019-03-06, status=1, ipAttribution=)]
    2019-07-14 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1909760, encodeId=7f701909e603a, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Aug 07 08:18:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008412, encodeId=3d002008412bb, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Wed Mar 20 15:18:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829968, encodeId=4d8a182996884, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jul 14 09:18:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316164, encodeId=7b4d131616408, content=<a href='/topic/show?id=7a1c4360e6e' target=_blank style='color:#2F92EE;'>#大出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43607, encryptionId=7a1c4360e6e, topicName=大出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Mar 06 05:18:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317491, encodeId=129b131e491d0, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Mar 06 05:18:00 CST 2019, time=2019-03-06, status=1, ipAttribution=)]
    2019-03-06 cmsvly
  5. [GetPortalCommentsPageByObjectIdResponse(id=1909760, encodeId=7f701909e603a, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Aug 07 08:18:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008412, encodeId=3d002008412bb, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Wed Mar 20 15:18:00 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829968, encodeId=4d8a182996884, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jul 14 09:18:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316164, encodeId=7b4d131616408, content=<a href='/topic/show?id=7a1c4360e6e' target=_blank style='color:#2F92EE;'>#大出血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43607, encryptionId=7a1c4360e6e, topicName=大出血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Mar 06 05:18:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317491, encodeId=129b131e491d0, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Mar 06 05:18:00 CST 2019, time=2019-03-06, status=1, ipAttribution=)]
    2019-03-06 fengyi812

相关威廉亚洲官网

N Engl J Med:癌症患者口服阿哌沙班预防静脉血栓栓塞 效果如何?

2018年12月,发表于《N Engl J Med》上的一项研究,考察了癌症患者,服用阿哌沙班预防静脉血栓栓塞(VTE)的效果。

Eur Heart J:接受消融的卒中风险房颤患者服用阿哌沙班的疗效!

由此可见,在接受射频消融的卒中高风险房颤患者持续使用阿哌沙班在出血、卒中和认知功能方面是安全且有效的。需要进一步的研究来减少与消融相关的急性脑损伤。

JAMA Neurol:中风预防人群抗凝血剂颅内出血风险差异研究——阿司匹林vs口服抗凝剂

研究认为,每日15-20mg利伐沙班会导致患者颅内出血风险增加,低剂量的利伐沙班或阿哌沙班则较为安全

NEJM:阿哌沙班预防癌症患者的静脉血栓栓塞

在开始化疗的中高风险门诊癌症患者中,阿哌沙班治疗可降低静脉血栓栓塞率,且明显低于安慰剂。阿哌沙班的大出血发生率高于安慰剂。

J Manag Care Spec Pharm:阿哌沙班vs华法林对老年NVAF患者HCRU和成本的影响

发表在《J Manag Care Spec Pharm》的一项研究考察了阿哌沙班vs华法林对老年非瓣膜性房颤(NVAF)患者的健康医疗资源使用(HCRU)和成本的影响

Circulation:阿哌沙班可降低晚期肾病/房颤患者的大出血、血栓栓塞和死亡风险

进行透析的晚期肾病(ESKD)患者被排除在房颤(AF)进行直接口服抗凝剂的临床试验外。近期的数据引起了人们对达比加群和利伐沙班安全性的担忧,但阿哌沙班尚未有评估,虽然目前的标签支持其应用于该人群。现研究人员尝试确定阿哌沙班在依赖透析的ESKD和AF患者中的应用模式及其相关预后。研究人员对包括美国肾脏数据系统的医疗保险受益人进行回顾性队列研究。筛选开始进行口服抗凝剂治疗的依赖透析的ESKD和AF患者